CAMP4 THERAPEUTICS CORPORATION CAMP
Regular-session close
After hours · Nov 20, 4:01 PM ET
- YTD
- -38.17%
- 1 year
- +7.98%
- Market cap
- 237.84M
- Revenue (ttm)
- 350.00K
- EPS (ttm)
- -2.11
- Shares out
- 20.16M
- Forward P/E
- -2.52
- YTD return
- -38.17%
- 1-year return
- +7.98%
- Volume
- 89.48K
- Avg volume
- 239.46K
- Open
- 3.95
- Previous close
- 4.00
- Day's range
- 3.78 – 4.00
- 52-week range
- 2.90 – 7.75
- Price target
- 19.91 (+425.3%)
Key statistics
- 50-day average
- 8.46
- 200-day average
- 8.46
- Enterprise value
- 162.90M
- Price / sales
- 436.63
- Total cash
- 12.61M
- Total debt
- 10.52M
- Short % of float
- 2.51%
Fundamental scorecard
7 of 25 checks passed on CAMP’s reported financials
7of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 8, 2024 | May 1, 2024 | -0.92 | — | — | — |
| Jun 6, 2024 | Feb 1, 2024 | -3.22 | — | — | — |
| Jan 9, 2024 | Nov 1, 2023 | -2.30 | — | — | — |
| Oct 5, 2023 | Aug 1, 2023 | 0.46 | — | — | — |
| Jul 10, 2023 | May 1, 2023 | 0.92 | — | — | — |
| Apr 27, 2023 | Feb 1, 2023 | 0.23 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2024 | William Blair | init | — | Outperform |
| Nov 5, 2024 | Leerink Partners | init | — | Outperform |
| Nov 5, 2024 | JP Morgan | init | — | Overweight |
| Nov 5, 2024 | Piper Sandler | init | — | Overweight |
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- camp4tx.com
News
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Camp4 Therapeutics Q3 EPS $(0.37) Misses $(0.18) Estimate, Sales $1.899M Beat $1.850M Estimate
CAMP4 Therapeutics Receives CTA Approval From Regulatory Authorities And Ethics Committees Of Multiple EU Countries To Initiate Global Phase 1/2 ASCEND Clinical Trial Of CMP-002 At Trial Sites In European Union
Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10
Your note
Sign in to keep a note on CAMP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| 5AM PARTNERS VI, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 14, 2024 | 0 |
| AH EQUITY PARTNERS BIO I, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 14, 2024 | 0 |
| ENAVATE SCIENCES GP, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 14, 2024 | 0 |
| HOLTZMAN STEVEN H | Director | Conversion of Exercise of derivative security | Oct 14, 2024 | 108,946 |
| MANDEL-BREHM JOSH | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 14, 2024 | 272,357 |
| NASHAT AMIR H. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 14, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | 1.13% | 227,300 | 1.72M | Oct 30, 2024 |
| Fidelity Growth Company Fund | 0.85% | 171,200 | 1.30M | Oct 30, 2024 |
| Fidelity Growth Company K6 Fund | 0.26% | 52,404 | 397.22K | Oct 30, 2024 |
| Fidelity Series Growth Company Fund | 0.22% | 43,500 | 329.73K | Oct 30, 2024 |
